Sinovac faces Nasdaq action over late 2025 report

Sinovac Biotech Ltd. reports that Nasdaq notified the company it had regained compliance with periodic filing and interim financial requirements as of May 8, 2026, after timely filing its 2024 Form 20-F and a mid-2025 Form 6-K as required.

Rhea-AI Filing Summary

Sinovac Biotech Ltd. reports that Nasdaq notified the company it had regained compliance with periodic filing and interim financial requirements as of May 8, 2026, after timely filing its 2024 Form 20-F and a mid-2025 Form 6-K as required.

The same update explains that Nasdaq later issued a Staff Determination on May 22, 2026 because Sinovac did not timely file its Form 20-F for the year ended December 31, 2025. Under a one-year panel monitoring period, this noncompliance could lead to suspension and delisting.

Sinovac has requested a hearing before the Nasdaq panel and an additional stay, which automatically pauses any suspension of its securities for 22 calendar days from the Staff Determination while the hearing process moves forward.

Positive

• None.

Negative

• Nasdaq Staff Determination for noncompliance: Nasdaq issued a delist determination letter on May 22, 2026 because Sinovac did not timely file its Form 20-F for the year ended December 31, 2025, putting its Nasdaq listing at risk pending the hearing outcome.

Insights

Equity listing and disclosure analyst

Sinovac risks Nasdaq delisting over a late 2025 annual report but has initiated the appeal process.

Sinovac Biotech confirms that it had regained Nasdaq compliance in May 2026 after completing its 2024 Form 20-F and a 2025 interim Form 6-K. However, Nasdaq has now issued a Staff Determination because the 2025 Form 20-F was not filed on time.

The company is under a one-year panel monitor, so repeat noncompliance with the Periodic Filing Rule can trigger suspension and delisting. By requesting a hearing and additional stay, Sinovac secures at least a 22‑day pause on any suspension while the panel reviews its response under Nasdaq Rule 5815(d)(4)(C).

Future company disclosures about completing the 2025 Form 20-F and the outcome of the requested Nasdaq hearing will clarify whether Sinovac maintains its Nasdaq listing or faces continued listing pressure.

Key Figures

Regained compliance date: May 8, 2026 Panel decision deadline: May 11, 2026 Staff Determination date: May 22, 2026 +4 more

7 metrics

Regained compliance date May 8, 2026 Date Nasdaq deemed Sinovac back in compliance with periodic filing rules

Panel decision deadline May 11, 2026 Deadline to complete 2024 Form 20-F and 2025 interim Form 6-K filings

Staff Determination date May 22, 2026 Date Nasdaq issued delist determination for late 2025 Form 20-F

Monitoring period length 1 year Duration of mandatory panel monitor starting from May 20, 2026

Automatic stay period 22 calendar days Length of automatic suspension stay after hearing request

2024 annual period Year ended December 31, 2024 Covered by timely filed Form 20-F used to regain compliance

2025 annual period Year ended December 31, 2025 Covered by late Form 20-F that triggered Staff Determination

Key Terms

Periodic Filing Rule, Nasdaq Listing Rules 5250(c)(1), Panel Monitor, Staff Determination, +1 more

5 terms

Periodic Filing Rule regulatory

"the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1)"

A periodic filing rule is a regulatory requirement that publicly traded companies deliver regular financial and operational reports—typically quarterly and annually—to securities regulators and the public. These routine updates act like a company’s report card or regular vehicle inspection, giving investors timely, standardized information about revenue, expenses, cash flow and risks so they can monitor performance, compare peers and make informed buy-or-sell decisions.

Nasdaq Listing Rules 5250(c)(1) regulatory

"regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1)"

Nasdaq Listing Rule 5250(c)(1) is a stock-exchange requirement that companies listed on Nasdaq must file their regular financial reports with regulators on schedule. Investors care because missing or late filings can prompt Nasdaq to suspend trading in the stock or begin delisting procedures, much like a store losing its license for failing to keep required records; that outcome can sharply reduce liquidity and investor confidence.

Panel Monitor regulatory

"the Company will be subject to a mandatory panel monitor (the “Panel Monitor”) for a period of one year"

A panel monitor is a flat electronic display — similar to a television for a computer — that shows text, charts and images using a thin screen panel (like LCD or LED). Investors care because sales, pricing and supply of these displays affect the revenue and profitability of manufacturers and retailers, and changes in demand can signal broader trends in consumer electronics and enterprise spending.

Staff Determination regulatory

"received a delist determination letter (the “Staff Determination”) from Nasdaq dated May 22, 2026"

A staff determination is a formal decision or finding made by agency or company employees who handle reviews and enforcement, rather than by higher-level boards or executives. Think of it like a referee’s ruling during a game: it resolves a specific procedural or compliance question and can affect whether a filing, claim, or product moves forward, the timing of approvals, and potential legal or market consequences for investors.

Nasdaq Listing Rule 5815(d)(4)(C) regulatory

"The Company will have the opportunity to respond and present to the Panel as provided by Nasdaq Listing Rule 5815(d)(4)(C)."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq notice did Sinovac Biotech Ltd. (SVA) receive in May 2026?

Sinovac received a Nasdaq notification dated May 20, 2026 confirming it had regained compliance with periodic filing and interim financial requirements as of May 8, 2026, after filing its 2024 Form 20-F and a mid-2025 Form 6-K as required by a prior panel decision.

Why did Nasdaq issue a Staff Determination against Sinovac (SVA)?

Nasdaq’s Staff Determination dated May 22, 2026 states Sinovac failed to timely file its Form 20-F for the year ended December 31, 2025. This lapse means the company no longer complies with the Nasdaq Periodic Filing Rule, triggering potential suspension and delisting procedures under the panel monitoring framework.

What is the one-year panel monitor affecting Sinovac Biotech (SVA)?

Nasdaq’s letter explains Sinovac will be subject to a mandatory panel monitor for one year from May 20, 2026. If the company again falls out of compliance with the Periodic Filing Rule during this period, Staff will issue a delist determination and Sinovac must seek another hearing to contest it.

How is Sinovac responding to the Nasdaq delisting risk?

Sinovac has requested a hearing before the Nasdaq panel regarding the May 22, 2026 Staff Determination and asked for a further stay of any suspension. The hearing request automatically stays suspension of its securities for 22 calendar days from that determination while the panel considers the case.

What earlier filings helped Sinovac (SVA) regain Nasdaq compliance?

Sinovac regained compliance by filing its annual report on Form 20-F for the year ended December 31, 2024 and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K, all completed by the May 11, 2026 deadline set by the Nasdaq panel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:00 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-32371

SINOVAC BIOTECH LTD.

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒     Form 40-F      ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINOVAC BIOTECH LTD.
	By:	/s/ Nan Wang
	Name:	Nan Wang
	Title:	Chief Financial Officer
Date: May 29, 2026

1

Exhibit Index

Exhibit 99.1 Press Release

2

Exhibit 99.1

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

BEIJING, China May 29, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

The Notification Letter also stated that the Company will be subject to a mandatory panel monitor (the “Panel Monitor”) for a period of one year from the date of such letter. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Periodic Filing Rule that was the subject of the exception, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Panel if the initial Panel is unavailable. The Company will have the opportunity to respond and present to the Panel as provided by Nasdaq Listing Rule 5815(d)(4)(C).

Subsequently, the Company received a delist determination letter (the “Staff Determination”) from Nasdaq dated May 22, 2026, stating that because the Company has not timely filed its annual report on Form 20-F for the year ended December 31, 2025 (the “2025 Annual Report”), the Company no longer complies with the Periodic Filing Rule. Therefore, in accordance with the Panel Monitor, unless the Company timely requests a hearing before the Panel regarding the Staff Determination by May 29, 2026, the Company’s securities would be subject to suspension and delisting.

Accordingly, the Company has today requested a hearing before the Panel. Such hearing request automatically stays the suspension of the Company’s securities for a period of 22 calendar days from the date of the Staff Determination. The Company has also requested a further stay of any suspension action pending the completion of the hearing process.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The Company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive^®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu^®), the world’s first H1N1 influenza vaccine (Panflu.1^®), and CoronaVac^®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the Company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the Company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, including the Company’s statements related to the timing and actions taken to regain compliance with Nasdaq listing rules. Such statements are based upon the Company’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the completion and filing of the 2025 Annual Report, and actions taken to regain compliance with the Nasdaq listing rules, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279 9779

Email: ir@sinovac.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 11.4 KB